阿胶治疗肿瘤相关性贫血的效果及安全性  

The Efficacy and Safety of Ejiao in the Treatment of Cancer Related Anemia

作　　者：武琛 邹济源 WU Chen;ZOU Jiyuan(Department of Spleen and Stomach,Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital,Beijing 101300,China)

机构地区：[1]北京中医医院顺义医院脾胃科,北京101300

出　　处：《中国卫生标准管理》2024年第14期140-143,共4页China Health Standard Management

摘　　要：目的探讨阿胶治疗肿瘤相关性贫血(cancer related anemia,CRA)的效果及安全性。方法选取北京中医医院顺义医院2020年5月—2022年10月收治的98例肿瘤化疗相关贫血患者为研究对象。采取随机数字表法分组,各49例。对照组给予硫酸亚铁片等常规基础治疗,观察组加用阿胶治疗。比较2组临床疗效、血液学指标、中医证候积分,同时观察用药期间不良反应。结果观察组临床总有效率为91.84%,高于对照组的69.39%,差异有统计学意义(P<0.05);治疗后,观察组红细胞计数(red blood cell count,RBC)、血红蛋白(hemoglobin,Hb)、血细胞比容(hematocrit,HCT)、红细胞平均体积(mean red blood cell volume,MCV)、红细胞平均血红蛋白含量(mean erythrocyte hemoglobin content,MCH)、红细胞平均血红蛋白浓度(mean erythrocyte hemoglobin concentration,MCHC)高于对照组,红细胞分布宽度(red blood cell distribution width,RDW)及血小板(platelets,PLT)低于对照组,中医证候积分低于对照组,差异有统计学意义(P<0.05)。2组用药期间未出现明显不良反应。结论阿胶治疗CRA的效果显著,可有效改善血红蛋白等各项血常规指标,恢复贫血症状,且治疗期间无明显不良反应,安全性较高。Objective To explore the efficacy and safety of ejiao in the treatment of cancer related anemia(CRA).Methods A total of 98 patients with tumor chemotherapy-associated anemia admitted to Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital from May 2020 to October 2022 were selected as the study objects.Random number table method was used to group 49 cases in each group.The control group was given routine basic treatment such as ferrous sulfate tablets,and the observation group was given ejiao treatment.The clinical efficacy,hematological indexes and TCM syndrome scores of the two groups were compared,and adverse reactions were observed during the treatment.Results The total clinical effective rate of the observation group was 91.84%,higher than 69.39%of the control group,and the difference was statistically significant(P<0.05).After treatment,red blood cell count(RBC),hemoglobin(Hb),hematocrit(HCT),mean red blood cell volume(MCV),mean erythrocyte hemoglobin content(MCH)and mean erythrocyte hemoglobin concentration(MCHC)in the observation group were higher than those in the control group,red blood cell distribution width(RDW)and platelets(PLT)were lower than those in the control group,and TCM syndrome scores were lower than those in the control group,the differences were statistically significant(P<0.05).There were no obvious adverse reactions in the two groups.Conclusion Ejiao has a significant effect on the treatment of CRA,and the blood routine indexes such as hemoglobin can be effectively improved,anemia symptoms can be recovered,and there is no obviousadverse reaction during treatment,and the safety is high.

关 键 词：阿胶 肿瘤相关性贫血 血红蛋白 血常规 疗效 安全性 

分 类 号：R281[医药卫生—中药学]